1358 Evaluation Webform

­­­­­­­

An Evolution in Cancer Management: Immune Checkpoint Inhibitors Enhancing Patient Outcomes

We greatly value your opinion. Your responses in this evaluation will be used in future planning of new courses and offerings for members of the healthcare team.
Click on the “Submit” button when you have finished the evaluation and the “Next” button to obtain your certificate.

Strongly Agree Agree Neutral Disagree Strongly Disagree
Describe the similarities and differences in the mechanisms of action of the immune checkpoint inhibitors, anti–cytotoxic T-lymphocyte–associated protein 4 (CTLA-4) and anti–programmed cell death protein 1/programmed cell death protein ligand 1 (PD-1/PDL-1)
Interpret the clinical efficacy data associated with the use of PD-1/PD-L1 immune checkpoint inhibitors
Appropriately manage the adverse effects associated with the use of PD-1/PD-L1 immune checkpoint inhibitors and how to manage them
Utilize biomarkers to predict response rates and improve therapy selection for patients receiving immunotherapy
Provide appropriate care and counsel for patients and their families
Strongly Agree Agree Neutral Disagree Strongly Disagree
The faculty were effective in presenting the material
The content was evidence based
The educational material provided useful information for my practice
The activity enhanced my current knowledge base
The activity provided appropriate and effective opportunities for active learning (e.g., case studies, discussion, Q&A, etc.)
The opportunities provided to assess my own learning were appropriate (e.g., questions before, during or after the activity)
Very confident Somewhat confident Unsure Not very confident
Your confidence level